

Philippine National Formulary 8th ed. Essential Medicines List 2019 as of November 2, 2022 with newly approved medicines as of January 27, 2025

Please be informed that the 8th Edition of the Philippine National Formulary (PNF) Essential Medicines List (EML) 2019 (as of November 2, 2022) is in the PhilHealth website through the following link:

https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11_022022.pdf

Prepared by the Department of Health, the PNF includes medicines that satisfy the priority health care needs of the population and are selected based on evidence of their efficacy, safety, and comparative cost effectiveness (DOH AO 2016-0034).

Annexed to this Advisory are the added medicines in the PNF that was recommended by the Health Technology Assessment Committee (HTAC) and approved by the Department of Health.

The latest edition of PNF is being used as reference by the Philippine Health Insurance Corporation (PhilHealth) in financing quality health care services being provided to all Filipinos as mandated by RA 7875, as amended.

Health care providers shall ensure that PNF drugs are always available for their usual case-mix, which will then be used as basis / reference for claims reimbursements and performance monitoring.

For the guidance of all concerned.

(Sgd.) EDWIN M. MERCADO, MD, MHA, MMSc
Acting President and Chief Executive Officer

Date Signed: February 17, 2025



Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
 Citystate Centre, 709 Shaw Boulevard, Pasig City
 (02) 8662-2588 www.philhealth.gov.ph
 PhilHealthOfficial teamphilhealth

Annex

Added medicines in the Philippine National Formulary as of January 27, 2025

Medicine	Department Circular	Date of Inclusion in PNF
2024		
Rotavirus Vaccine (Live, Attenuated) - Monovalent G1P[8] strain: 1.5 mL oral suspension containing not less than (NLT) 106.0 cell culture infectious dose (CCID ₅₀) of live, attenuated rotavirus monovalent G1P[8] in a pre-filled glass syringe	DOH-DC No. 2024-0051	January 11, 2024
Rotavirus Vaccine (Live, Attenuated) - Pentavalent G1, G2, G3, G4 and P1A[8] strains: 2 mL solution for oral administration containing live reassortant rotaviruses - G1, G2, G3, G4 and P1A[8] with a minimum of 2.0-2.8 x 10 ⁶ infectious units (IU) per reassortant dose in a 2 mL single dose ready-to-use plastic tube (single dose plastic dosing tube in individual foil pouch per box)	DOH-DC No. 2024-0051	January 11, 2024
Rotavirus Vaccine (Live, Attenuated) - Pentavalent G1, G2, G3, G4, and G9 strains for children less than one (1) year of age: 2 mL oral suspension containing live, attenuated bovine-human rotavirus reassortant - G1, G2, G3, G4, and G9 with ≥105.6 Focus-forming Unit (FFU) per serotype (NLT 6.30 log ₁₀ CCID ₅₀ per dose) in 5 mL single dose LDPE plastic ampoule.	DOH-DC No. 2024-0051	January 11, 2024
Abacavir/Lamivudine 120mg/60mg dispersible tablet	DOH-DC No. 2024-0498	November 22, 2024
Donepezil hydrochloride 23 mg film-coated tablet	DOH-DC No. 2024-0498	November 22, 2024
Levonorgestrel 52 mg intrauterine delivery (IUD) system	DOH-DC No. 2024-0498	November 22, 2024
Levonorgestrel 75 mg subdermal implant	DOH-DC No. 2024-0498	November 22, 2024
Sodium Chloride + Potassium Chloride + Calcium Lactate + Pentahydrate 1.544 g/83.16 mg / 63.13 mg per sachet powder for reconstitution	DOH-DC No. 2024-0498	November 22, 2024
Tenofovir + Lamivudine (in combination with Dolutegravir Oral: 300 mg + 300 mg + 50 mg tablet	DOH-DC No. 2024-0498	November 22, 2024
Tenofovir /Lamivudine /Dolutegravir Oral: 300 mg + 300 mg + 50 mg	DOH-DC No. 2024-0498	November 22, 2024
Dapirivine 25 mg vaginal delivery system (vaginal ring)	DOH-DC No. 2024-0498	November 22, 2024